Last reviewed · How we verify
NCT03864575: NICE-COMBO
An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors
Phase 2 trial testing Celecoxib 400 mg in Metastatic Cancer in 68 participants. Status unknown.
15 June 2021
Quick facts
| Lead sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 15 August 2019 |
| Primary completion | 15 June 2021 |
| Estimated completion | 15 June 2021 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Celecoxib 400 mg — full drug profile →
Conditions studied
- Metastatic Cancer — all drugs for Metastatic Cancer →
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain — full company profile →
Who can join
18 and older, any sex, with Metastatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label study to evaluate the safety and the anti-tumor activity of the combination of nivolumab and celecoxib. The total numbers of participants to be enrolled will be up to 68 participants, depending on the investigated dose of celecoxib during the safety run-in phase.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
The updated landscape of tumor microenvironment and drug repurposing.
Jin MZ, Jin WL. · · 2020 · cited 900× · PMID 32843638 · DOI 10.1038/s41392-020-00280-x -
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695 -
Neutrophils in the era of immune checkpoint blockade.
Faget J, Peters S, Quantin X, Meylan E, et al · · 2021 · cited 94× · PMID 34301813 · DOI 10.1136/jitc-2020-002242 -
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.
Varayathu H, Sarathy V, Thomas BE, Mufti SS, et al · · 2021 · cited 62× · PMID 34123767 · DOI 10.3389/fonc.2021.559161 -
Repurposing non-oncology small-molecule drugs to improve cancer therapy: Current situation and future directions.
Fu L, Jin W, Zhang J, Zhu L, et al · · 2022 · cited 47× · PMID 35256933 · DOI 10.1016/j.apsb.2021.09.006 -
Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.
Ding AS, Routkevitch D, Jackson C, Lim M. · · 2019 · cited 47× · PMID 31396227 · DOI 10.3389/fimmu.2019.01715 -
Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.
Tang F, Tie Y, Hong W, Wei Y, et al · · 2021 · cited 35× · PMID 33258011 · DOI 10.1245/s10434-020-09371-z -
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies.
Ngiow SF, Young A. · · 2020 · cited 31× · PMID 32849557 · DOI 10.3389/fimmu.2020.01633
Verify or expand the search:
- PubMed search for NCT03864575
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Celecoxib 400 mg
Trials testing the same drug.
- NCT03586934 — Multimodal Analgesia in Shoulder Arthroplasty · Phase 3 · withdrawn
Other recruiting trials for Metastatic Cancer
Currently open trials in the same condition.
- NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
- NCT07144085 — Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. · Phase 1 · recruiting
- NCT06963723 — Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer · NA · recruiting
- NCT06311851 — Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases · Phase 1, PHASE2 · recruiting
- NCT07011862 — COBRA: Cancer, Older Adults, Balance and Resistance Activities · NA · recruiting
Other Cliniques universitaires Saint-Luc- Université Catholique de Louvain trials
Trials by the same sponsor.
- NCT07464938 — New Tools and Predictive Markers in the Prognosis of Hypoxic-ischemic Encephalopathy Following Cardiac Arrest · NA · recruiting
- NCT07173036 — Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification Accordin · NA · not yet recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
- NCT07588490 — Treatment of Acute Low Back Pain With Transcutaneous Electrical Neurostimulation in Emergency Departments · NA · recruiting
- NCT07161219 — Implementation of New Exercise Protocols in Cardiac Rehabilitation. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03864575 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Last refreshed: 12 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03864575.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing